Pneumacare awarded CE mark for  revolutionary respiratory measurement systems

27 July 2011

Cambridge-based PneumaCare Limited has announced that it has been awarded the CE mark for its novel PneumaScan devices that use 3D imaging technology for measuring and assessing respiration.

"Passing this important milestone allows PneumaCare to launch into full clinical use of the PneumaScan. Doctors can now begin to take advantage of PneumaScan’s entirely non-contact approach to medical measurement to the benefit of patients," says Dr Simon Baker, PneumaCare’s product manager. "Clinical and commercial use of PneumaScan has already started at Papworth and Addenbrooke’s Hospitals in Cambridge, and Sheffield Children’s Hospital. It will soon begin at the John Radcliffe Hospital in Oxford, as well as other clinics in the UK and Europe."

The CE Marking approval process certified that PneumaCare is in full quality compliance with European Union (EU) Directives for Medical Devices in the design, production, sales and services for the PneumaScan Structured Light Plethysmography instrument and accessories.

"The fact that we have achieved this within only two years is attributable to the unusually focused cooperation between the clinicians, researchers and engineers involved in the PneumaScan’s design and production," commented Dr Ward Hills, PneumaCare’s CEO.

The PneumaScan products are revolutionary non–contact respiratory monitoring systems that have the huge advantage of being able to provide richer information on a broader patient population swiftly and relatively easily. A major benefit is that by using PneumaScan, patients can be assessed while breathing naturally without the need to breathe into, interact with, or have any contact with the apparatus. This non-contact assessment reduces both the risk of infection and instrument running costs. The ease of use also allows PneumaScan to be used with a much larger portion of the population than other approaches.

"Because it’s simple, fast and compact, this non-invasive technology has great potential for a range of specialties, including anaesthetics and the emergency department," said Dr Richard Iles, a consultant in respiratory and paediatric medicine at Addenbrooke’s Hospital and PneumaCare’s Chief Medical Officer. "It will be particularly valuable in the clinic for patients under the age of six with problems like cystic fibrosis and asthma. In addition, many adult lung conditions like COPD may begin in early childhood, so if PneumaScan makes it possible for us to identify them earlier, we will be able to start treatment earlier."

PneumaScan is already being used in clinics, pre- and post-operative assessments, drug testing, and device development by both public and private health care providers. Further applications of PneumaCare’s proprietary Structured Light Plethysmography technology, developed in close partnership with the clinical community, include home care, neonatal, critical care, and rehabilitation applications.

Source: PneumaScan.


To top